Singapore biotech company Mirxes is in early talks to go public via a blank-check company affiliated with veteran private equity healthcare investor Fu Wei, The Business Times reports, citing people familiar with the matter. The company is said to be in discussions with Summit Healthcare Acquisition, which raised $200 million in a June IPO. The combined company would reportedly be valued at $1.2 billion. Read more.
Related Posts
FoxWayne, Aerami Therapeutics SPAC Deal Worth $195M: Report
The SPAC executed a non-binding letter of intent with Aerami earlier this month, according to a securities filing.
Are D&O Insurance Rates ‘Bottoming Out’ This Year?
Directors and officers insurance rates will start to “bottom out” for legacy firms and public companies that did not go public in the last three years, according to one D&O insurance analyst.
Trump Media Plunges After Release of First deSPAC S-1
Shares have plunged 65% since the stock's debut last month on the Nasdaq, when it briefly peaked at $79.38 before spiraling steadingly.
SPAC Advisor ARC Group Gets Abu Dhabi Regulator’s Approval to Offer Services
ARC Group, a SPAC and IPO advisory firm with a focus on Asia, has received an In-Principle Approval from the Financial Services Regulatory Authority of Abu Dhabi Global Market.